About the Journal
STEM CELLS Translational Medicine® is a monthly, peer-reviewed, online only, open access journal. STEM CELLS Translational Medicine works to advance the utilization of cells for clinical therapy. By bridging stem cell molecular and biological research and helping speed translations of emerging lab discoveries into clinical trials, the journal will help move applications of these critical investigations closer to accepted best patient practices and ultimately improve outcomes.
The journal encourages original research articles and concise reviews describing laboratory investigations of stem cells, including their characterization and manipulation, and the translation of their clinical aspects from the bench to patient care. STEM CELLS Translational Medicine covers all aspects of translational cell studies, including bench research, first-in-human case studies, and relevant clinical trials.
Scope
STEM CELLS Translational Medicine covers:
Human Clinical Articles
- First-in-human case studies
- Phase I/II clinical trials
- Negative clinical results
Cell-Based Drug Development, Screening, and Toxicology
- Derivation, characterization, and differentiation for clinical use
- In vivo models
- In vitro models
- Throughput systems
Cord Blood
- Umbilical cord blood and tissue-based therapies
- Accessory cell populations
- Ex-vivo expansion strategies
- Engineering and manufacturing of cord blood immune cells
- Modulation of endogenous cell and tissue repair
- Cord blood and cord tissue banking
- Malignant and non-malignant disease treated by cord blood transplantation
- Cord blood and cord tissue in regenerative medicine
Enabling Technologies for Cell-Based Clinical Translation
- Cell tracking
- Cell delivery vehicles
- Biomaterials
- Devices
- Imaging
- Diagnostics
Fetal and Neonatal Stem Cells
- Derivation, characterization, and differentiation for clinical use with in vivo validation
- Cell banking
- Therapeutic potential
- Animal models
- Translational preclinical studies
- Clinical applications
- First-in-human case studies
- Phase I/II clinical trials
- Negative clinical results
Manufacturing for Regenerative Medicine
- GMP aspects
- Cell-based processing/expansion
- Cell-based potency/storage
- Quality assurance/control
- Scale-up and production
- Cell-based therapies release criteria
- Regulations for manufacturing
Pluripotent Stem Cells
- Derivation, characterization, and differentiation for clinical use with in vivo validation
- Cell banking
- Therapeutic potential
- Animal models
- Translational preclinical studies
- Clinical applications
- First-in-human case studies
- Phase I/II clinical trials
- Negative clinical results
Standards, Protocols, Policies, and Regulations for Cell-Based Therapies
- Cell standards
- Intellectual property relevant to clinical translation
- Cell toxicology/tumorigenesis and other assays
- Regulations for clinical trials
Stem Cells and Cancer
- Characterization
- Therapeutic targets
- Animal models
- Translational preclinical studies
- Clinical applications
- First-in-human case studies
- Phase I/II clinical trials
- Negative clinical results
Tissue Engineering and Regenerative Medicine
- Applications for cell-based strategies in pathological in vivo conditions
- Tissue engineering
- Medical device and artificial organ development
- Cell transplantation and technologies that will maintain, improve, or restore the function of diseased organs
- Therapeutic potential
- Animal models
- Translations preclinical studies
- Clinical applications
- First-in-human case studies
- Phase I/II clinical trials
- Negative clinical results
Tissue-Specific Progenitor and Stem Cells
- Derivation, characterization, and differentiation for clinical use with in vivo validation
- Cell banking
- Therapeutic potential
- Animal models
- Translational preclinical studies
- Clinical applications
- First-in-human case studies
- Phase I/II clinical trials
- Negative clinical results
Disclaimer
While the publisher and Editorial Board make every effort to see that no inaccurate or misleading data, opinions, or statements appear in this journal, they wish to state that the data and opinions in the articles and advertisements herein are the responsibility of the contributor or advertiser concerned. Accordingly, the publisher, Editorial Board, and their respective employees, officers, and agents accept no liability whatsoever for the consequences of any such inaccurate or misleading data, opinion or statement. While every effort is made to ensure drug doses and other quantities are presented accurately, readers are advised that new methods and techniques involving drug usage described within this journal should be followed only in conjunction with the drug manufacturer's own published literature.
Abstracting and indexing information
Biomedical Reference Collection: Corporate Edition (EBSCO, full text coverage)
Biotechnology Source (EBSCO, full text coverage)
MEDLINE Complete with Full Text (EBSCO, full text coverage)
EMBASE (Elsevier)
Scopus (Elsevier)
PubMed, via both MEDLINR indexing & PMC deposit
Biological Abstracts (Clarivate Analytics)
BIOSIS Previews (Clarivate Analytics)
Science Citation Index Expanded (Clarivate Analytics)
Web of Science (Clarivate Analytics)
Chemical Abstracts Service (CAS)
